Emyria Wins Major Insurer Backing for MDMA-Assisted Therapy

Emyria wins major insurer backing for MDMA-assisted therapy

WA biotech Emyria has won major backing from Australia’s biggest health insurer to fund its psychedelic-assisted therapy program aimed at treating post-traumatic stress disorder.

Medibank funds MDMA-assisted psychotherapy for PTSD in Western Australia - Medical Republic

The insurer and therapy provider say they’re looking at expanding to eastern states too.

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program - Psychedelic Alpha

Australia’s largest private health insurer, Medibank, has launched a first-of-its-kind funding program for MDMA-assisted therapy for PTSD as part of its ‘innovative psychotherapy program’. That makes it the first payor in the country to back psychedelic-assisted psychotherapy. The AUD $10 million (~USD $6.5 million) investment will fund patient access to MDMA therapy, as well as a long-term… Source

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic. Key Highlights:Medibank (ASX: MPL) to fund eligible customer participation i…